제약용 유리관 시장 예측(-2032년) : 유리 유형, 제조 공정, 형상, 유통 채널, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Pharmaceutical Glass Tubing Market is accounted for $16.09 billion in 2025 and is expected to reach $24.04 billion by 2032 growing at a CAGR of 5.9% during the forecast period. Pharmaceutical glass tubing is a specialized type of glass used in the production of containers for storing and delivering medications. Made primarily from borosilicate or soda-lime glass, it offers high chemical resistance, thermal stability, and durability. This glass ensures the purity and safety of pharmaceutical products by preventing interactions with the container. It is commonly used to manufacture vials, ampoules, and syringes in the pharmaceutical and biotechnology industries.

Market Dynamics:

Driver:

Rising investment in healthcare infrastructure

The increasing demand for high-quality pharmaceutical packaging is driving investment in healthcare infrastructure globally. Governments and private entities are focusing on improving drug storage and delivery systems to ensure safety and efficacy. Advanced pharmaceutical glass tubing provides superior chemical resistance and minimizes contamination risks, making it a preferred choice. Technological innovations in tubing materials enhance durability and support efficient drug administration methods. Additionally, the rising prevalence of chronic diseases is fuelling investments in improved medical packaging solutions.

Restraint:

Risk of glass delamination

Glass delamination, a phenomenon where thin layers peel away from the internal surface of a vial, poses a significant challenge to pharmaceutical packaging. This issue can lead to compromised drug stability and potential health risks for patients. Manufacturers must implement rigorous quality control measures to mitigate these risks, increasing production costs. Additionally, the complexity of maintaining consistent glass quality across different formulations adds to the restraint in market expansion.

Opportunity:

Stringent regulatory standards for drug safety

Compliance with these standards ensures high-quality, contamination-free packaging driving demand for advanced glass tubing solutions. Specialized coatings and improved glass compositions help pharmaceutical companies meet stringent safety requirements. As the focus on biologics and injectable drugs grows, the need for reliable and durable glass tubing rises. Companies investing in research and development to enhance product integrity are gaining a competitive edge in the market.

Threat:

Limited recycling and sustainability challenges

The complex composition of specialty glass makes recycling difficult, leading to environmental concerns. Manufacturers are exploring eco-friendly alternatives, but adoption remains slow due to cost and technical barriers. Additionally, the disposal of pharmaceutical glass waste must adhere to strict guidelines, further complicating sustainability efforts. Companies are under pressure to develop greener solutions while maintaining product efficacy and regulatory compliance.

Covid-19 Impact

The COVID-19 pandemic significantly influenced the pharmaceutical glass tubing market, both positively and negatively. Increased demand for vaccine packaging led to a surge in glass tubing production, boosting market growth. However, supply chain disruptions and raw material shortages caused delays in manufacturing and distribution. The pandemic underscored the importance of reliable pharmaceutical packaging for drug stability and safety. Companies have since focused on enhancing production efficiency to meet future healthcare crises.

The clear tubing segment is expected to be the largest during the forecast period

The clear tubing segment is expected to account for the largest market share during the forecast period, due to its transparency and chemical stability. Clear tubing facilitates easy drug inspection, ensuring quality control and safety for injectable medicines. Manufacturers prefer clear tubing for its compatibility with various formulations, reducing contamination risks. The growing adoption of biologic drugs and vaccines is further propelling demand for this segment.

The hospital & diagnostic centers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospital & diagnostic centers segment is predicted to witness the highest growth rate, due to the increasing number of healthcare facilities and diagnostic labs is driving the need for reliable drug packaging solutions. Advancements in medical treatments, including precision therapies, require high-quality glass tubing for drug delivery. The emphasis on patient safety and drug efficacy further strengthens demand within this segment. Additionally, hospital expansions and government healthcare initiatives support sustained market growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by robust healthcare infrastructure and rising pharmaceutical production. Countries like China, India, and Japan have established themselves as key players in drug manufacturing and packaging innovation. Government policies promoting healthcare advancements are fuelling market growth across the region. The presence of leading pharmaceutical glass tubing manufacturers enhances supply chain efficiency and affordability.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, propelled by strict regulatory standards and technological advancements. The growing focus on biologics and injectable drugs is driving demand for superior glass tubing materials. Pharmaceutical companies in the U.S. and Canada are heavily investing in innovative packaging solutions to enhance drug stability. Rising healthcare expenditure and stringent drug safety requirements further accelerate market expansion.

Key players in the market

Some of the key players profiled in the Pharmaceutical Glass Tubing Market include Schott AG, Gerresheimer AG, Nipro Corporation, SGD Pharma, Stevanato Group S.p.A., West Pharmaceutical Services, Inc., Corning Incorporated, DWK Life Sciences GmbH, Ardagh Group S.A., Bormioli Pharma S.p.A., Piramal Glass Private Limited, Shandong Weigao Group Medical Polymer Products Co., Ltd., Nihon Yamamura Glass Co., Ltd., Amino GmbH, and Richland Glass Company, Inc.

Key Developments:

In May 2025, SCHOTT Pharma, announced that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla from Serum Institute of India (SII). SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide.

In November 2024, SGD Pharma expands capacity of siliconized glass vials with the announcement of a new siliconization line at its Center of Excellence for Type I glass in France. The company enhances its already extensive range of in-house services by internalizing its glass siliconization offer, further ensuring responsiveness, security of supply and improved flexibility of vial sizes.

Glass Types Covered:

• Borosilicate Glass (Type I)
• Soda-Lime Glass (Types II & III)
• Other Glass Types

Manufacturing Processes Covered:

• Molded Glass Tubing
• Tubular Glass Tubing

Forms Covered:

• Clear Tubing
• Colored Tubing
• Frosted Tubing
• Other Forms

Distribution Channels Covered:

• Direct Sales
• Distributors
• Online Channels

Applications Covered:

• Vials
• Ampoules
• Cartridges
• Syringes
• Test Tubes
• Bottles
• Other Applications

End Users Covered:

• Pharmaceutical Manufacturers
• Contract Manufacturing Organizations (CMOs)
• Biotechnology Companies
• Hospital & Diagnostic Centers
• Research & Development Labs
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pharmaceutical Glass Tubing Market, By Glass Type

• 5.1 Introduction
• 5.2 Borosilicate Glass (Type I)
• 5.3 Soda-Lime Glass (Types II & III)
• 5.4 Other Glass Types

6 Global Pharmaceutical Glass Tubing Market, By Manufacturing Process

• 6.1 Introduction
• 6.2 Molded Glass Tubing
• 6.3 Tubular Glass Tubing

7 Global Pharmaceutical Glass Tubing Market, By Form

• 7.1 Introduction
• 7.2 Clear Tubing
• 7.3 Colored Tubing
• 7.4 Frosted Tubing
• 7.5 Other Forms

8 Global Pharmaceutical Glass Tubing Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Direct Sales
• 8.3 Distributors
• 8.4 Online Channels

9 Global Pharmaceutical Glass Tubing Market, By Application

• 9.1 Introduction
• 9.2 Vials
• 9.3 Ampoules
• 9.4 Cartridges
• 9.5 Syringes
• 9.6 Test Tubes
• 9.7 Bottles
• 9.8 Other Applications

10 Global Pharmaceutical Glass Tubing Market, By End User

• 10.1 Introduction
• 10.2 Pharmaceutical Manufacturers
• 10.3 Contract Manufacturing Organizations (CMOs)
• 10.4 Biotechnology Companies
• 10.5 Hospital & Diagnostic Centers
• 10.6 Research & Development Labs
• 10.7 Other End Users

11 Global Pharmaceutical Glass Tubing Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Schott AG
• 13.2 Gerresheimer AG
• 13.3 Nipro Corporation
• 13.4 SGD Pharma
• 13.5 Stevanato Group S.p.A.
• 13.6 West Pharmaceutical Services, Inc.
• 13.7 Corning Incorporated
• 13.8 DWK Life Sciences GmbH
• 13.9 Ardagh Group S.A.
• 13.10 Bormioli Pharma S.p.A.
• 13.11 Piramal Glass Private Limited
• 13.12 Shandong Weigao Group Medical Polymer Products Co., Ltd.
• 13.13 Nihon Yamamura Glass Co., Ltd.
• 13.14 Amino GmbH
• 13.15 Richland Glass Company, Inc.